What is meant by “personalized” or “individualized” medicine?

Currently, much of medical practice is based on “standards of care” that are determined by averaging patient responses across large cohorts. The theory has been that everyone should get the same care based on clinical trials. Personalized Medicine is the concept of managing a patient’s health based on the individual patient’s specific characteristics.

Does the company have any tests on the market?

CCC Diagnostics, LLC currently markets the DirectHit™ Test Panel for Breast Cancer. DirectHit is a diagnostic test to assist physicians in designing personalized treatment regimens for patients fighting breast cancer. DirectHit allows physicians and patients to exclude ineffective drug treatments resulting in optimal use of the time window for treatment, reduction of side effects and significant financial savings.

Are additional tests in development?

Yes, retrospective clinical trials are currently being conducted to evaluate DirectHit for gastrointestinal cancer patients. These trials are being performed in conjunction with several hospitals in Maryland. The trial encompasses esophageal, rectal, colon, pancreatic, gastric and duodenal cancers. Drugs/biomarkers being evaluated include: 5-FU/Thymidylate Synthase, Platinum Drugs/ERCC1, and Irinotecan/TOPO I. Early results are encouraging and indicate greater than 85% accuracy for DirectHit predictions. These results were published as an abstract at the ASCO Meeting, June 2009 in Orlando, Florida. Efforts are underway to organize a number of hospitals in Maryland and Illinois to conduct a large scale retrospective study of DirectHit on G.I. cancers.

Are there any publications describing the DirectHit™?

Yes, please see the list of CCCD’s publications and presentations

Who can I contact if I have a question or need more information?

For additional information, please contact CCCD’s Technical Director:

Scott Deamond
Phone – 410-633-4885 x1071
Email – Scott@CCCdiag.com